

งานบริหารงานวิจัยและนวัตกรรม  
เลขที่รับ 861  
วันที่ 14/12/65  
เวลา



คณะเภสัชศาสตร์  
เลขที่รับ 6978  
วันที่ 9 ส.ค. 2565  
เวลา 9:39 น.  
รหัสแฟ้ม.....  
เก็บเอกสารถึงปี พ.ศ.....

งานบริหารและส่งเสริมการวิจัย  
กองบริหารงานวิจัย มหาวิทยาลัยมหิดล  
โทร. 02-849-6252 โทรสาร. 02-849-6247

ที่ อว 78.016/ว 6468

วันที่ 8 ธันวาคม 2565

เรื่อง ประชาสัมพันธ์การเปิดรับข้อเสนอโครงการ จากแหล่งทุน National Institutes of Health (NIH) ประเภท Research Project Grant รอบ Cycle I/2023 หัวข้อ "NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)" หมายเลขประกาศทุน PAR-23-034

- สิ่งที่ส่งมาด้วย
1. รายละเอียดประกาศทุน PAR-23-034
  2. ขั้นตอนการสมัครขอรับทุน

เรียน คณบดี / ผู้อำนวยการ

ด้วยแหล่งทุน National Institutes of Health (NIH) ประเภท Research Project Grant รอบ Cycle I/2023 หัวข้อ "NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)" หมายเลขประกาศทุน PAR-23-034 โดยเปิดรับข้อเสนอโครงการ ตั้งแต่วันที่ 5 มกราคม 2566 จนถึงวันที่ 5 กุมภาพันธ์ 2566 เวลา 17.00 น. ตามเวลาประเทศไทย ทั้งนี้ โครงการที่เสนอขอทุนให้ปฏิบัติ ตามประกาศมหาวิทยาลัยมหิดล เรื่องหลักเกณฑ์และอัตราเงินค่าธรรมเนียมพัฒนาการวิจัยของมหาวิทยาลัยและส่วน งานที่จัดเก็บจากโครงการวิจัยที่ได้รับเงินอุดหนุนจากแหล่งทุนภายนอกมหาวิทยาลัย พ.ศ. 2560 และขอให้ดำเนินการ ตามที่ระบุในหนังสือชักชวนแนวปฏิบัติ เรื่องมาตรฐานการวิจัยของโครงการวิจัย รายละเอียดดังกล่าวแนบมาด้วยนี้ ทั้งนี้ อาจารย์/นักวิจัยที่สนใจสามารถศึกษารายละเอียดเพิ่มเติมได้ตามเอกสารที่แนบมาด้วยนี้ หรือเว็บไซต์ของแหล่ง ทุนที่ <https://grants.nih.gov/grants/guide/pa-files/PAR-23-034.html>

ในการนี้ กองบริหารงานวิจัย มหาวิทยาลัยมหิดล จึงขอแจ้งข่าวประกาศทุนมายังท่าน เพื่อ โปรดประชาสัมพันธ์ทุนวิจัยดังกล่าวให้บุคลากรในหน่วยงานของท่านทราบโดยทั่วกัน และขอให้อาจารย์/นักวิจัย **โปรดแจ้งความประสงค์การจัดส่งข้อเสนอ ภายในวันที่ 5 มกราคม 2566 และจัดส่งข้อเสนอโครงการวิจัยผ่าน ส่วนงานต้นสังกัดมายังกองบริหารงานวิจัยเพื่อตรวจสอบรายละเอียดข้อเสนอโครงการฉบับสมบูรณ์ภายในวันที่ 27 มกราคม 2566** ทั้งนี้ หากส่วนงานแจ้งความประสงค์การจัดส่งข้อเสนอโครงการวิจัยหลังจากวันที่ 27 มกราคม 2566 มหาวิทยาลัยขอสงวนสิทธิ์ในการยื่นข้อเสนอโครงการวิจัยเพื่อขอรับทุนดังกล่าว จึงเรียนมาเพื่อโปรดทราบและประชาสัมพันธ์ข่าวทุนวิจัยดังกล่าวต่อไปด้วย จักขอบคุณยิ่ง

งานบริหารงานวิจัยและนวัตกรรม  
หมัฟพ  
9 ธ.ค. 65

*(Handwritten Signature)*

เรียน คณบดี (มหาวิทยาลัยฯ)

- เสนอเปิดสอน NIH ประกาศเรื่องขอเสนอโครงการ (ศาสตราจารย์ ดร. นายแพทย์ ภัทรชัย กิริติสิน) # PAR-23-034 โดยส่งพร้อมเอกสารแนบ และ ร้องอธิการบดีฝ่ายวิจัย  
รายละเอียดของเอกสารที่แนบ ผู้สนใจสามารถดูได้ที่เว็บไซต์ของมหาวิทยาลัย  
ภายใน 5 ม.ค. 2566 หากจัดส่ง proposal ดังกล่าวพร้อมเอกสารแนบ 26 ม.ค. 2566  
เพื่อส่งให้สำนักบริหารงานวิจัยต่อไป

- ส่งเอกสารแนบทุกภาคไว้
  - ส่งอีเมลข่าวประชาสัมพันธ์
- ผู้ประสานงาน : นางสาวจิตติพร นวลละออง

นางสาวจิตติพร นวลละออง  
9 ธ.ค. 65

ไปรษณีย์  
อ.ดิฉัน  
13/12/65

ทราบ  
14/12/65

รับเรื่องคืนจากห้องคณบดี+รองคณบดี  
วันที่ 14 ธ.ค. 2565



# Department of Health and Human Services

## Part 1. Overview Information

### Participating Organization(s)

National Institutes of Health ([NIH \(http://www.nih.gov\)](http://www.nih.gov))

### Components of Participating Organizations

National Library of Medicine ([NLM \(https://www.nlm.nih.gov/\)](https://www.nlm.nih.gov/))

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Data Science Strategy ([ODSS \(https://datascience.nih.gov/about/odss\)](https://datascience.nih.gov/about/odss))

### Funding Opportunity Title

NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)

### Activity Code

[R01 \(//grants.nih.gov/grants/funding/ac\\_search\\_results.htm?text\\_curr=r01&Search.x=0&Search.y=0&Search\\_Type=Activity\)](http://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r01&Search.x=0&Search.y=0&Search_Type=Activity) Research Project Grant

### Announcement Type

Reissue of [PAR-18-896 \(https://grants.nih.gov/grants/guide/pa-files/PAR-18-896.html\)](https://grants.nih.gov/grants/guide/pa-files/PAR-18-896.html)

### Related Notices

None

### Funding Opportunity Announcement (FOA) Number

PAR-23-034

### Companion Funding Opportunity

None

### Number of Applications

See [Section III. 3. Additional Information on Eligibility](#).

### Assistance Listing Number(s)

93.879, 93.310

### Funding Opportunity Purpose

The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.

## Key Dates

### Posted Date

October 06, 2022

### Open Date (Earliest Submission Date)

January 05, 2023

### Letter of Intent Due Date(s)

Not Applicable

The following table includes NIH [standard due dates \(https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm\)](https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm) marked with an asterisk.

Application Due Dates			Review and Award Cycles		
New	Renewal / Resubmission / Revision (as allowed)	AIDS	Scientific Merit Review	Advisory Council Review	Earliest Start Date
February 05, 2023 *	March 05, 2023 *	May 07, 2023 *	July 2023	October 2023	December 2023
June 05, 2023 *	July 05, 2023 *	September 07, 2023 *	November 2023	January 2024	April 2024
October 05, 2023 *	November 05, 2023 *	January 07, 2024 *	March 2024	May 2024	July 2024
February 05, 2024 *	March 05, 2024 *	May 07, 2024 *	July 2024	October 2024	December 2024
June 05, 2024 *	July 05, 2024 *	September 07, 2024 *	November 2024	January 2025	April 2025
October 05, 2024 *	November 05, 2024 *	January 07, 2025 *	March 2025	May 2025	July 2025
February 05, 2025 *	March 05, 2025 *	May 07, 2025 *	July 2025	October 2025	December 2025
June 05, 2025 *	July 05, 2025 *	September 07, 2025 *	November 2025	January 2026	April 2026
October 05, 2025 *	November 05, 2025 *	January 07, 2026 *	March 2026	May 2026	July 2026

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

### Expiration Date

January 08, 2026

### Due Dates for E.O. 12372

Not Applicable

### Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the [SF424 \(R&R\) Application Guide \(https://grants.nih.gov/grants/guide/uri\\_redirect.htm?id=82400\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=82400), except where instructed to do otherwise (in this FOA or in a Notice from [NIH Guide for Grants and Contracts \(https://grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11164\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11164)).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in [Section IV](#). When the program-



specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

**Applications that do not comply with these instructions may be delayed or not accepted for review.**

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You **must** use one of these submission options to access the application forms for this opportunity.

1. Use the NIH ASSIST system to prepare, submit and track your application online.

Apply Online Using ASSIST

2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and [eRA Commons](#) (<https://grants/guide/ApplyButtonSplash.cfm?dest=https://public.era.nih.gov/commons/>) to track your application. Check with your institutional officials regarding availability.
3. Use [Grants.gov](#) (<https://grants/guide/ApplyButtonSplash.cfm?dest=GrantsGov&oppNum=PAR-23-034>) **Workspace** to prepare and submit your application and [eRA Commons](#) (<https://grants/guide/ApplyButtonSplash.cfm?dest=http://public.era.nih.gov/commons/>) to track your application.

## Table of Contents

### [Part 1. Overview Information](#)

#### [Key Dates](#)

### [Part 2. Full Text of Announcement](#)

#### [Section I. Funding Opportunity Description](#)

#### [Section II. Award Information](#)

#### [Section III. Eligibility Information](#)

#### [Section IV. Application and Submission Information](#)

#### [Section V. Application Review Information](#)

#### [Section VI. Award Administration Information](#)

#### [Section VII. Agency Contacts](#)

#### [Section VIII. Other Information](#)

## Part 2. Full Text of Announcement

### Section I. Funding Opportunity Description

The National Library of Medicine (NLM) supports innovative research aimed at advancing biomedical informatics and data science. Biomedical informatics applies theories and analytical processes or methods to data to improve decision-making and human health. The [NLM Strategic Plan](#) ([https://www.nlm.nih.gov/pubs/plan/lrp17/NLM\\_StrategicReport2017\\_2027.html](https://www.nlm.nih.gov/pubs/plan/lrp17/NLM_StrategicReport2017_2027.html)) outlines a platform for biomedical discovery and data-powered health, integrating streams of complex and interconnected data that can be translated into scientific insights, clinical care, public health practices, and personal wellness. NIH defines [data science](#) ([https://datascience.nih.gov/sites/default/files/nih\\_strategic\\_plan\\_for\\_data\\_science\\_final\\_508.pdf](https://datascience.nih.gov/sites/default/files/nih_strategic_plan_for_data_science_final_508.pdf)) as “the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data.” Research problems that can be addressed with biomedical informatics and data science are broad, but should align with NLM’s focus for the acceleration of data-driven discovery by the advancement of human health using the exposome (from the intracellular environment to the built environment), broadening analytics across heterogeneous data sources including natural language processing and deep learning, and increasing computable biomedical knowledge, (e.g., diagnostics), and decision-analytic models.

The NLM strategic plan reinforces the need to accelerate discovery by enhancing health through data-driven research. Applications proposed to NLM should align with the strategic plan. Proposals should emphasize novel methods to foster data driven discovery in biomedical and clinical health sciences that are domain-independent, reusable/reproducible and use FAIR (Findable, Accessible, Interoperable, Reusable) standards for increased harmonization.

NLM supports innovative research projects focused on biomedical data that combine elements of computer science and information technology to optimize the use of information and technology to improve individual and public health and biomedical research. Research areas of interest to NLM include, but are not limited to:

- Development of novel approaches enabling analysis and discovery at scale across biomedical domains and health care sectors, including those leveraging high-performance cloud computing and federated learning
- Development and demonstration of innovative informatics methods and data science techniques for informing biological, clinical, public health, and social science research.



- Computational approaches integrating structured and unstructured data, natural language processing, automated metadata assignment.
- Advanced information retrieval and knowledge discovery from very large and/or heterogeneous data sets
- Multi-level, reusable, data analytic models, simulations, information visualization, and presentation approaches to enhance decisions, learning or understanding of biological and clinical processes
- Approaches to assess and address algorithmic bias and/or fairness and health equity
- Innovative analytic methods to advance decision support that are generalizable within and across underserved populations
- Applying natural language processing to unstructured health-related data, including Electronic Health Record (EHR) data, to increase provider-patient health care understanding
- Informatics approaches that translate basic biomedical research to clinical methods to support patient and provider decision making
- Data science methods and approaches that enhance the quality, security, understandability and utility of data, information, or knowledge related to health and biomedicine
- Informatics methods and approaches to improve public health and population-level health outcomes
- Using biomedical informatics and data science to address health disparities and health equity

Research in biomedical informatics and data science is inherently multidisciplinary, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Applications that propose team science approaches are encouraged. NLM expects that investigators will employ rigorous, scientifically defensible research techniques leading to sound empirical and reproducible evidence. These techniques may include quantitative and qualitative approaches, *in silico* experiments, simulation studies, model generation and testing, computer-based analytical techniques supporting clinical and non-clinical decisions through novel uses of computational analytics, text mining and natural language processing, network inference and pathway analyses, ontologies, and other advanced approaches. For NLM support, a research project's innovation should be centered in the development and testing of novel data science or biomedical informatics methods and approaches.

Applications submitted to this funding opportunity should focus on a well-defined research problem, a rigorous research design, based on preliminary studies, and advance the field of informatics or data science to improve human health. NLM will consider supporting projects where the primary focus of informatics or data science is applied to a clinical or disease domain when the approach is novel and will benefit findings in the domain, although priority will be placed on funding applications that propose to develop tools and approaches that can be reproduced, generalized, and scaled to ensure maximum benefit is achieved. NLM will not support infrastructure or product development or continued development of existing software tools or knowledge resources as an endpoint of research funded through this FOA.

Potential applicants are strongly encouraged to discuss their proposed project with one of the Scientific/Research Contacts listed in Section VII for advice about the application process and suitability of the project for support by NLM.

**NOTE:** Under this FOA, NLM will support applications involving small, early-stage to Phase I clinical trials that are part of the evaluation component of the proposed research project. Applicants whose applications may include a clinical trial are strongly encouraged to contact one of the NLM Scientific Contacts listed in this FOA for guidance in advance of applying to ensure that their proposed project follows NIH clinical trials policies (<https://grants.nih.gov/policy/clinical-trials.htm>) and consistent with the types of clinical trial applications that NLM supports.

### Office of Data Science Strategy

ODSS is interested in stimulating early-stage investigators into biomedical research careers to employ novel or advanced data science approaches in broad domain knowledge to ensure meaningful, interpretable, and scalable from individual to community, and /or population-level health implications and/or biomedical discovery.

ODSS does NOT award grants. Please contact the relevant NIH ICO program contact listed for questions related to NIH ICO research priorities and funding.

[Need help determining whether you are doing a clinical trial? \(https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=82370\)](https://grants.nih.gov/grants/guide/url_redirect.htm?id=82370)

See [Section VIII, Other Information](#) for award authorities and regulations.

Investigators proposing NIH-defined clinical trials may refer to the [Research Methods Resources \(https://researchmethodsresources.nih.gov/\)](https://researchmethodsresources.nih.gov/) website for information about developing statistical methods and study designs.

## Section II. Award Information

### Funding Instrument

Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

### Application Types Allowed

New  
Renewal  
Resubmission

New  
Renewal



## Resubmission

The [OER Glossary \(//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11116\)](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11116) and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

**Clinical Trial?**

Optional: Accepting applications that either propose or do not propose clinical trial(s).

[Need help determining whether you are doing a clinical trial? \(https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=82370\)](https://grants.nih.gov/grants/guide/url_redirect.htm?id=82370)

**Funds Available and Anticipated Number of Awards**

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

**Award Budget**

Application budgets are limited to \$250,000 per year in direct costs and need to reflect the actual needs of the proposed project.

**Award Project Period**

The scope of the proposed project should determine the project period. The maximum project period is 4 years.

NIH grants policies as described in the [NIH Grants Policy Statement \(//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11120\)](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11120) will apply to the applications submitted and awards made from this FOA.

## Section III. Eligibility Information

### 1. Eligible Applicants

#### Eligible Organizations

##### Higher Education Institutions

- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

##### Nonprofits Other Than Institutions of Higher Education

- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

##### For-Profit Organizations

- Small Businesses
- For-Profit Organizations (Other than Small Businesses)

##### Local Governments

- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)

##### Federal Governments

- Eligible Agencies of the Federal Government
- U.S. Territory or Possession

##### Other



- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-domestic (non-U.S.) Entities (Foreign Institutions)

## Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) **are** eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations **are** eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement ([//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11118](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11118)), **are** allowed.

## Required Registrations

### Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications ([//grants.nih.gov/grants/guide/notice-files/NOT-OD-15-039.html](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-039.html)) states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

- System for Award Management (SAM)– ([https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=82390](https://grants.nih.gov/grants/guide/url_redirect.htm?id=82390)) Applicants must complete and maintain an active registration, **which requires renewal at least annually**. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  - NATO Commercial and Government Entity (NCAGE) Code ([//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11176](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11176)) – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
  - Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
- eRA Commons ([https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=11123](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11123)) - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their full SAM and Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- Grants.gov ([//grants.nih.gov/grants/guide/url\\_redirect.htm?id=82300](https://grants.nih.gov/grants/guide/url_redirect.htm?id=82300)) – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

### Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

## Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

## 2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement. ([//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11126](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11126))

## 3. Additional Information on Eligibility

### Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application ([https://grants.nih.gov/grants/policy/ningps/HTML5/section\\_2/2.3.7\\_policies\\_affecting\\_applications.htm#Submissi](https://grants.nih.gov/grants/policy/ningps/HTML5/section_2/2.3.7_policies_affecting_applications.htm#Submissi)). This means that the NIH will not accept:

- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.



- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see [2.3.9.4 Similar, Essentially Identical, or Identical Applications](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_2/2.3.9_application_receipt_information_and_deadlines.htm#Similar.) ([https://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_2/2.3.9\\_application\\_receipt\\_information\\_and\\_deadlines.htm#Similar.](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_2/2.3.9_application_receipt_information_and_deadlines.htm#Similar.))).

## Section IV. Application and Submission Information

### 1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in [Part 1](#) of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

### 2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the [SF424 \(R&R\) Application Guide](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=82400) ([https://grants.nih.gov/grants/guide/uri\\_redirect.htm?id=82400](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=82400)) except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

#### Page Limitations

All page limitations described in the SF424 Application Guide and the [Table of Page Limits](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11133) ([https://grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11133](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11133)) must be followed.

#### Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

#### SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

#### SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

#### SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

#### SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

#### R&R or Modular Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

#### R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

#### PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

#### PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

##### Research Strategy

**Significance:** If the application focus is to solve a problem, explain how the lack of an existing solution impedes the field of interest. Identify how the proposed research will fill key gaps in understanding the area of interest. If the application focus is to verify a novel hypothesis, substantiate that it is critical for the field that the hypothesis be verified or disproved.

**Approach:** The approach should be innovative, scalable, generalizable, and provide a well-defined rationale for its use. Knowledge-based evidence of other current work on the problem should be addressed.

**Resource Sharing Plan:** Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:



Applicants are expected to include a general plan for timely dissemination and sharing of data and resources, e.g., code, widely, as appropriate, and consistent with achieving the goals of the program in concert with NIH and NLM policies. A software dissemination plan, with appropriate timelines, is expected to be included to meet the goals of this initiative.

There is no prescribed single license for software produced through grants responding to this announcement. However, reviewers will be instructed to evaluate the dissemination plans relative to these goals:

A major goal of this FOA is the development of data science and biomedical informatics methods and tools that enable healthcare decision-making. Applicants should therefore include detailed plans for open dissemination of methods, software, and tools to the community such that they are readily usable and extensible, where applicable. These should be made freely available to biomedical researchers and educators. There is no prescribed license for software produced by applications responding to this announcement, but any software license selected by applicants should allow for unrestricted redistribution and modification of software.

Methods, tools, and software should be well documented and where applicable made available via version-controlled public repositories.

Where applicable, applicants should describe solutions for portable implementations to cloud computing environments.

Solutions that enhance reproducibility when used by the community and ability of the community to integrate into automated pipelines should be emphasized.

- Any developed software should be freely available to biomedical researchers, curators, and educators in the non-profit sector, such as institutions of education, research institutions, and government laboratories.
- The terms of software availability should include the ability of outside researchers to modify the source code and to share modifications with other colleagues as well as with the investigators. The terms should also permit the dissemination and commercialization of enhanced or customized versions of the software, or incorporation of the software or pieces of it into other software packages.
- To preserve utility to the community, the software should be transferable such that another individual or team can continue development if the original investigators are unwilling or unable to do so.

Resource sharing should focus on the following to ensure scalability and reusability:

- All applications, regardless of the amount of direct costs requested for any one year, should address a Data Management and Sharing Plan for the purpose of reusability
- Software or other resources resulting from the research must include a plan for resource sharing the resources including coding methods and code editing upon post publication use
- Data Management and Sharing Plans must be consistent with the funding agency's current Data Management & Sharing Policy
- Considerations should be given to how and where data will be housed and shared with other researchers

## Appendix:

Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

- No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

## PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the **Study Record: PHS Human Subjects and Clinical Trials Information** form or **Delayed Onset Study** record.

### Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

### Delayed Onset Study

Note: Delayed onset (<https://grants.nih.gov/grants/glossary.htm#DelayedOnsetStudy>) does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.

## PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

## Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the [NIH Grants Policy Statement](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11137) ([https://grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11137](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11137)), and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

## 3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA



Commons, and Grants.gov

#### 4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=82380](https://grants.nih.gov/grants/guide/url_redirect.html?id=82380)), the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=11128](https://grants.nih.gov/grants/guide/url_redirect.html?id=11128)) (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=11123](https://grants.nih.gov/grants/guide/url_redirect.html?id=11123)), NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

#### 5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review. ([https://grants.nih.gov/grants/policy/nihgps/html5/section\\_10/10.10.1\\_executive\\_orders.htm](https://grants.nih.gov/grants/policy/nihgps/html5/section_10/10.10.1_executive_orders.htm))

#### 6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=11120](https://grants.nih.gov/grants/guide/url_redirect.html?id=11120)).

Pre-award costs are allowable only as described in the NIH Grants Policy Statement ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=11143](https://grants.nih.gov/grants/guide/url_redirect.html?id=11143)).

#### 7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide (<https://grants.nih.gov/grants/how-to-apply-application-guide.html>). If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues (<https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/dealing-with-system-issues.htm>) guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

##### Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=11146](https://grants.nih.gov/grants/guide/url_redirect.html?id=11146)) for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.

NOTE: Applications with proposed budget beyond the budget ceiling and the proposed project period beyond 4 years will be deemed non-responsive and, therefore, be withdrawn.

#### Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy ([https://grants.nih.gov/grants/guide/url\\_redirect.html?id=82299](https://grants.nih.gov/grants/guide/url_redirect.html?id=82299)). Any instructions provided here are in addition to the instructions in the policy.

## Section V. Application Review Information

### 1. Criteria



Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the [NIH mission \(https://grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11149\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11149) are evaluated for scientific and technical merit through the NIH peer review system.

The focus of this funding opportunity is the use and application of biomedical informatics for data-driven discovery. Emphasis is on innovation and novel methods in biomedical and clinical health sciences that are reusable/reproducible, and use FAIR principles. Multidisciplinary teams are expected. Proposed clinical trial applications must include study design, methods, and intervention that address important questions or unmet needs. Clinical trial results may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Infrastructure development or continued development of existing software or knowledge resources as an endpoint, would be considered non-responsive.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

## Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

## Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

### Significance

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

#### In addition, for applications involving clinical trials

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

### Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

#### In addition, for applications involving clinical trials

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

### Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

#### In addition, for applications involving clinical trials

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?

### Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of



development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

#### **In addition, for applications involving clinical trials**

Does the application adequately address the following, if applicable

##### *Study Design*

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

##### *Data Management and Statistical Analysis*

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

#### **Environment**

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

#### **In addition, for applications involving clinical trials**

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

#### **Additional Review Criteria**

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

#### **Study Timeline**

##### **Specific to applications involving clinical trials**

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSA, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

#### **Protections for Human Subjects**

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to



their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the [Guidelines for the Review of Human Subjects \(//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11175\)](https://grants.nih.gov/grants/guide/redirect.htm?id=11175).

### **Inclusion of Women, Minorities, and Individuals Across the Lifespan**

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the [Guidelines for the Review of Inclusion in Clinical Research \(//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11174\)](https://grants.nih.gov/grants/guide/redirect.htm?id=11174).

### **Vertebrate Animals**

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the [Worksheet for Review of the Vertebrate Animal Section \(//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11150\)](https://grants.nih.gov/grants/guide/redirect.htm?id=11150).

### **Biohazards**

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

### **Resubmissions**

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

### **Renewals**

For Renewals, the committee will consider the progress made in the last funding period.

### **Revisions**

Not applicable.

### **Additional Review Considerations**

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

#### **Applications from Foreign Organizations**

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

#### **Select Agent Research**

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

#### **Resource Sharing Plans**

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) [Data Sharing Plan \(//grants.nih.gov/grants/guide/url\\_redirect.htm?id=11151\)](https://grants.nih.gov/grants/guide/redirect.htm?id=11151); (2) [Sharing Model Organisms \(https://sharing.nih.gov/other-sharing-policies/model-organism-sharing-policy#policy-overview\)](https://sharing.nih.gov/other-sharing-policies/model-organism-sharing-policy#policy-overview); and (3) [Genomic Data Sharing Plan \(GDS\) \(https://sharing.nih.gov/genomic-data-sharing-policy\)](https://sharing.nih.gov/genomic-data-sharing-policy).

#### **Authentication of Key Biological and/or Chemical Resources**

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

#### **Budget and Period of Support**

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.



## 2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NLM, in accordance with [NIH peer review policy and procedures \(//grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11154\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11154), using the stated [review criteria](#). Assignment to a Scientific Review Group will be shown in the eRA Commons. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

- Scientific and technical merit of the proposed project as determined by scientific peer review
- Application innovation and advancement of methods/approaches
- Availability of funds
- Relevance of the proposed project to program priorities

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process where only those applications having the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the NLM Board of Regents. The following will be considered in making funding decisions:

- Scientific and technical merit of the proposed project as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed project to program priorities.
- Portfolio balance.

## 3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the [eRA Commons \(//grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11123\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11123). Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the [NIH Grants Policy Statement \(//grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11120\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11120).

# Section VI. Award Administration Information

## 1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the [NIH Grants Policy Statement \(https://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_2/2.5.1\\_just-in-time\\_procedures.htm\)](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_2/2.5.1_just-in-time_procedures.htm).

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the [Award Conditions and Information for NIH Grants \(https://grants.nih.gov/grants/policy/nihgps/HTML5/part\\_ii\\_subpart\\_b.htm\)](https://grants.nih.gov/grants/policy/nihgps/HTML5/part_ii_subpart_b.htm) website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

**ClinicalTrials.gov:** If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration and Results System Information Website (<https://register.clinicaltrials.gov> (<https://register.clinicaltrials.gov/>)). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see <https://grants.nih.gov/policy/clinical-trials/reporting/index.htm> (<https://grants.nih.gov/policy/clinical-trials/reporting/index.htm>)

**Institutional Review Board or Independent Ethics Committee Approval:** Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

**Data and Safety Monitoring Requirements:** The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at [http://grants.nih.gov/grants/policy/hs/data\\_safety.htm](http://grants.nih.gov/grants/policy/hs/data_safety.htm) ([//grants.nih.gov/grants/policy/hs/data\\_safety.htm](https://grants.nih.gov/grants/policy/hs/data_safety.htm)) and in the application instructions (SF424 (R&R) and PHS 398).



Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

## 2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the [NIH Grants Policy Statement \(//grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11120\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11120) as part of the NoA. For these terms of award, see the [NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General \(//grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11157\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11157) and [Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities \(//grants.nih.gov/grants/guide/uri\\_redirect.htm?id=11159\)](https://grants.nih.gov/grants/guide/uri_redirect.htm?id=11159), including of note, but not limited to:

- [Federalwide Research Terms and Conditions \(https://grants.nih.gov/grants/policy/nihgps/HTML5/section 3/3.1 federalwide standard terms and conditions for research grants.htm\)](https://grants.nih.gov/grants/policy/nihgps/HTML5/section%203/3.1%20federalwide%20standard%20terms%20and%20conditions%20for%20research%20grants.htm)
- [Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment \(https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-041.html\)](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-041.html)
- [Acknowledgment of Federal Funding \(https://grants.nih.gov/grants/policy/nihgps/HTML5/section 4/4.2.1 acknowledgment of federal funding.htm\)](https://grants.nih.gov/grants/policy/nihgps/HTML5/section%204/4.2.1%20acknowledgment%20of%20federal%20funding.htm)

If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identify, sexual orientation, and pregnancy). This includes ensuring programs are accessible to persons with limited English proficiency and persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> (<https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html>) and <https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html>

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> (<https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html>) and <https://www.lep.gov> (<https://www.lep.gov/>).
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including reasonable accommodations and making services accessible to them, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html> (<http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>).
- HHS funded health and education programs must be administered in an environment free of sexual harassment, see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html> (<https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>). For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm> (<https://grants.nih.gov/grants/policy/harassment.htm>).
- For guidance on administering programs in compliance with applicable federal conscience protection and associated anti-discrimination laws see <https://www.hhs.gov/conscience/conscience-protections/index.html> (<https://www.hhs.gov/conscience/conscience-protections/index.html>) and <https://www.hhs.gov/conscience/religious-freedom/index.html> (<https://www.hhs.gov/conscience/religious-freedom/index.html>).

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at <https://www.hhs.gov/ocr/about-us/contact-us/index.html> (<https://www.hhs.gov/ocr/about-us/contact-us/index.html>) or call 1-800-368-1019 or TDD 1-800-537-7697.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant's integrity, business ethics, and record of performance under Federal



awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 "Federal awarding agency review of risk posed by applicants." This provision will apply to all NIH grants and cooperative agreements except fellowships.

## Cooperative Agreement Terms and Conditions of Award

Not Applicable

### 3. Reporting

When multiple years are involved, recipients will be required to submit the [Research Performance Progress Report \(RPPR\)](https://grants.nih.gov/grants/rppr/index.htm) (<https://grants.nih.gov/grants/rppr/index.htm>) annually and financial statements as required in the [NIH Grants Policy Statement](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.4.1_reporting.htm) ([https://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_8/8.4.1\\_reporting.htm](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.4.1_reporting.htm))

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the [NIH Grants Policy Statement](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.6_closeout.htm) ([https://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_8/8.6\\_closeout.htm](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.6_closeout.htm)). NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at [www.fsrs.gov](http://www.fsrs.gov) ([https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=11170](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11170)) on all subawards over the threshold. See the [NIH Grants Policy Statement](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_4/4.1.8_federal_funding_accountability_and_transparency_act_ffata.htm) ([https://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_4/4.1.8\\_federal\\_funding\\_accountability\\_and\\_transparency\\_act\\_ffata .htm](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_4/4.1.8_federal_funding_accountability_and_transparency_act_ffata.htm)) for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and 2 CFR Part 200.113 and Appendix XII to 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than \$10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 and 2 CFR Part 200 – Award Term and Condition for Recipient Integrity and Performance Matters.

## Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

### Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: <http://grants.nih.gov/support/> (<https://grants.nih.gov/support/>) (preferred method of contact)

Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)

Email: [GrantsInfo@nih.gov](mailto:GrantsInfo@nih.gov) (<mailto:GrantsInfo@nih.gov>) (preferred method of contact)

Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)

Contact Center Telephone: 800-518-4726

Email: [support@grants.gov](mailto:support@grants.gov) (<mailto:support@grants.gov>)

### Scientific/Research Contact(s)

**For Public Health and Population Health Informatics or, Social and Behavioral Science Applications Involving Informatics:**

Meryl Sufian, PhD

National Library of Medicine (NLM)

Telephone: 301-496-4671

Email: [sufianm@mail.nih.gov](mailto:sufianm@mail.nih.gov) (<mailto:sufianm@mail.nih.gov>)

**For Clinical Informatics or Clinical Research Informatics:**

Lyn Hardy, PhD, RN

National Library of Medicine (NLM)

Telephone: 301-594-1297

Email: [lynda.hardy@nih.gov](mailto:lynda.hardy@nih.gov) (<mailto:lynda.hardy@nih.gov>)



**For Basic Research Developing Novel Informatics Methods and Techniques:**

Yanli Wang, PhD  
National Library of Medicine (NLM)  
Telephone: 301-827-7092  
Email: [yanli.wang@nih.gov](mailto:yanli.wang@nih.gov) (<mailto:yanli.wang@nih.gov>)

**For Bioinformatics or Consumer Health Informatics:**

Allison Dennis, PhD  
National Library of Medicine (NLM)  
Telephone: 301-827-9721  
Email: [allison.dennis@nih.gov](mailto:allison.dennis@nih.gov) (<mailto:allison.dennis@nih.gov>)

**For Translational Informatics and Bioinformatics:**

Veerasamy "Ravi" Ravichandran, PhD  
National Library of Medicine (NLM)  
Telephone: 301-594-4882  
Email: [Veerasamy.Ravichandran@nih.gov](mailto:Veerasamy.Ravichandran@nih.gov) (<mailto:Veerasamy.Ravichandran@nih.gov>)

Lucy Hsu  
Office of Data Science Strategy  
Phone: 301-451-7961  
Email: [lucy.hsu@nih.gov](mailto:lucy.hsu@nih.gov) (<mailto:lucy.hsu@nih.gov>)

**Peer Review Contact(s)**

Zoe Huang, MD  
National Library of Medicine (NLM)  
Telephone: 301-496-4253  
Email: [huangz@mail.nlm.nih.gov](mailto:huangz@mail.nlm.nih.gov) (<mailto:huangz@mail.nlm.nih.gov>)

**Financial/Grants Management Contact(s)**

Samantha Tempchin  
National Library of Medicine (NLM)  
Telephone: 301-496-4222  
Email: [tempchins@mail.nih.gov](mailto:tempchins@mail.nih.gov) (<mailto:tempchins@mail.nih.gov>)

George Coy  
Office of Data Science Strategy  
Phone: 667-231-9522  
Email: [george.coy@nih.gov](mailto:george.coy@nih.gov) ([george.coy@nih.gov](mailto:george.coy@nih.gov))

## Section VIII. Other Information

Recently issued trans-NIH [policy notices](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11163) ([https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=11163](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11163)) may affect your application submission. A full list of policy notices published by NIH is provided in the [NIH Guide for Grants and Contracts](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11164) ([https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=11164](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11164)). All awards are subject to the terms and conditions, cost principles, and other considerations described in the [NIH Grants Policy Statement](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11120) ([https://grants.nih.gov/grants/guide/url\\_redirect.htm?id=11120](https://grants.nih.gov/grants/guide/url_redirect.htm?id=11120)).

**Authority and Regulations**

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.

[Weekly TOC for this Announcement](https://grants/guide/WeeklyIndex.cfm?10-07-22) (<https://grants/guide/WeeklyIndex.cfm?10-07-22>)  
[NIH Funding Opportunities and Notices](https://grants/guide/index.html) (<https://grants/guide/index.html>)



National Institutes of Health (<https://grants/oeer.htm>)  
Office of Extramural Research



(<http://www.hhs.gov/>) Department of Health  
and Human Services (HHS)





NIH... Turning Discovery Into Health<sup>®</sup>

**Note:** For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see [Help Downloading Files \(/grants/edocs.htm\)](http://grants.edocs.htm).



## ขั้นตอนการสมัครขอรับทุน National Institute of Health (NIH)

1. ผู้สมัครจะต้องแจ้งความประสงค์และนำส่งข้อมูลเข้ามายังกองบริหารงานวิจัย ภายในกำหนดเวลาแจ้งความประสงค์การจัดส่งข้อเสนอในหนังสือประชาสัมพันธ์ โดยนำส่งข้อมูลทางอีเมล [chittiporn.nua@mahidol.edu](mailto:chittiporn.nua@mahidol.edu) เพื่อขอเปิดบัญชี eRA commons และขอสร้างข้อเสนอโครงการในระบบออนไลน์ ASSIST ของแหล่งทุน NIH โดยแจ้งข้อมูลดังนี้

Name: Surname:

Email ([XXXX@mahidol.ac.th](mailto:XXXX@mahidol.ac.th) หรือ [XXXX@mahidol.edu](mailto:XXXX@mahidol.edu)):

Funding Opportunity Announcement (FOA) Number:

Application title:

Application due date:

2. ผู้สมัครขอรับทุนศึกษาประกาศทุน (Funding opportunity announcements หรือ FOA) อย่างละเอียด ตรวจสอบกำหนดการส่งข้อเสนอของมหาวิทยาลัย และสืบค้นข้อมูลที่เกี่ยวข้องกับงานวิจัยของตนเองผ่าน NIH RePORTER <https://reporter.nih.gov>
3. มหาวิทยาลัยสร้างบัญชี eRA commons และสร้างข้อเสนอโครงการในระบบ ASSIST ให้ผู้สมัครขอรับทุน ผู้ขอรับทุนจัดทำข้อเสนอโครงการและเอกสารที่เกี่ยวข้องตามข้อกำหนดของแหล่งทุนร่วมกับมหาวิทยาลัย
4. ผู้สมัครขอรับทุนนำส่งเอกสารข้อเสนอโครงการฉบับสมบูรณ์ผ่านหัวหน้าส่วนงานเพื่อขออนุมัติจัดส่งข้อเสนอโครงการผ่านระบบออนไลน์ ASSIST ตามกำหนดรับข้อเสนอของมหาวิทยาลัย\*\* กองบริหารงานวิจัยตรวจสอบข้อเสนอโครงการ เสนออนุมัตินำส่งข้อเสนอโครงการและจัดส่งข้อเสนอโครงการในนามของมหาวิทยาลัยไปยังแหล่งทุน

(\*\*หากผู้สมัครขอรับทุนนำส่งข้อเสนอโครงการให้กองบริหารงานวิจัยตรวจสอบล่าช้ากว่ากำหนดของมหาวิทยาลัย มหาวิทยาลัยขอสงวนสิทธิ์ในการรับข้อเสนอโครงการเพื่อนำส่งแหล่งทุนในรอบนั้นๆ)

01

- Find your FOA and Application due date

- Search NIH RePORTER

02

- Create your eRA commons ID

- Initiate Application in ASSIST

03

- Application preparing

- Letter of support and

04

- Validate Application

- Submission

สอบถามข้อมูลเพิ่มเติม คุณจิตติพร 02-8496252 [chittiporn.nua@mahidol.edu](mailto:chittiporn.nua@mahidol.edu)

หน่วยสนับสนุนการขอทุนวิจัยจากแหล่งทุนต่างประเทศ

Mahidol University: Supporting Unit for International Research Funding (MU: SURF)